PLIANT THERAPEUTICS, INC. Operating Lease Cost
PLIANT THERAPEUTICS, INC. (PLRX) reported Operating Lease Cost of $1.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-11
- PLIANT THERAPEUTICS, INC. operating lease, cost for the quarter ending 2026-06-30 was $1.50M, a 0.00% change year-over-year.
- PLIANT THERAPEUTICS, INC. operating lease, cost for the quarter ending 2026-03-31 was $1.51M, a 0.00% change year-over-year.
- PLIANT THERAPEUTICS, INC. operating lease, cost for the quarter ending 2025-12-31 was $1.50M, a 0.07% increase year-over-year.
- PLIANT THERAPEUTICS, INC. operating lease, cost for the quarter ending 2025-09-30 was $1.51M, a 1.63% decline year-over-year.
- PLIANT THERAPEUTICS, INC. operating lease, cost for fiscal 2025 was $6.02M, a 4.62% increase from fiscal 2024.
- PLIANT THERAPEUTICS, INC. operating lease, cost for fiscal 2024 was $5.76M, a 107.72% increase from fiscal 2023.
- PLIANT THERAPEUTICS, INC. operating lease, cost for fiscal 2023 was $2.77M, a 10.80% increase from fiscal 2022.
- PLIANT THERAPEUTICS, INC. operating lease, cost for fiscal 2022 was $2.50M, a 8.74% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 9 month as first filed | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.50M 10-Q · filed 2026-08-11 | $3.01M 10-Q · filed 2026-08-11 | $4.52M derived: sum of 3 quarters · filed 2026-08-11 | $6.02M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2026-03-31 | $1.51M 10-Q · filed 2026-05-11 | $3.01M derived: sum of 2 quarters · filed 2026-05-11 | $4.52M derived: sum of 3 quarters · filed 2026-05-11 | $6.02M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $3.01M derived: sum of 2 quarters · filed 2026-03-11 | $4.52M derived: sum of 3 quarters · filed 2026-08-11 | $6.02M 10-K · filed 2026-03-11 | |||
| 2025-09-30 | $1.51M 10-Q · filed 2025-11-06 | $3.01M derived: sum of 2 quarters · filed 2026-08-11 | $4.52M 10-Q · filed 2025-11-06 | $6.02M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-06-30 | $1.50M 10-Q · filed 2026-08-11 | $3.01M 10-Q · filed 2026-08-11 | $4.51M derived: sum of 3 quarters · filed 2026-08-11 | $6.05M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | $1.51M 10-Q · filed 2026-05-11 | $3.01M derived: sum of 2 quarters · filed 2026-05-11 | $4.54M derived: sum of 3 quarters · filed 2026-05-11 | $6.17M derived: sum of 4 quarters · filed 2026-05-11 | |||
| 2024-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $3.04M derived: sum of 2 quarters · filed 2026-03-11 | $4.66M derived: sum of 3 quarters · filed 2026-03-11 | $5.76M 10-K · filed 2026-03-11 | |||
| 2024-09-30 | $1.53M 10-Q · filed 2025-11-06 | $3.16M derived: sum of 2 quarters · filed 2025-11-06 | $4.25M 10-Q · filed 2025-11-06 | $4.76M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2024-06-30 | $1.63M 10-Q · filed 2025-08-07 | $2.60M 10-Q · filed 2025-08-07 | $3.23M derived: sum of 3 quarters · filed 2025-08-07 | $3.92M derived: sum of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | $972.00K 10-Q · filed 2025-05-08 | $1.60M derived: sum of 2 quarters · filed 2025-05-08 | $2.30M derived: sum of 3 quarters · filed 2025-05-08 | $2.97M derived: sum of 4 quarters · filed 2025-05-08 | |||
| 2023-12-31 | $629.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $1.33M derived: sum of 2 quarters · filed 2025-03-03 | $2.00M derived: sum of 3 quarters · filed 2025-03-03 | $2.77M 10-K · filed 2025-03-03 | |||
| 2023-09-30 | $698.00K 10-Q · filed 2024-11-07 | $1.37M derived: sum of 2 quarters · filed 2024-11-07 | $2.14M 10-Q · filed 2024-11-07 | $2.86M derived: sum of 4 quarters · filed 2025-03-03 | |||
| 2023-06-30 | $674.00K 10-Q · filed 2024-08-07 | $1.44M 10-Q · filed 2024-08-07 | $2.16M derived: sum of 3 quarters · filed 2025-03-03 | $2.82M derived: sum of 4 quarters · filed 2025-03-03 | |||
| 2023-03-31 | $770.00K 10-Q · filed 2024-05-06 | $700.00K 10-Q · filed 2023-05-09 | $1.49M derived: sum of 2 quarters · filed 2025-03-03 | $2.14M derived: sum of 3 quarters · filed 2025-03-03 | $2.74M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2022-12-31 | $718.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $1.37M derived: sum of 2 quarters · filed 2025-03-03 | $1.97M derived: sum of 3 quarters · filed 2025-03-03 | $2.50M 10-K · filed 2025-03-03 | $2.50M 10-K · filed 2023-03-09 | ||
| 2022-09-30 | $655.00K 10-Q · filed 2023-11-09 | $700.00K 10-Q · filed 2022-11-08 | $1.25M derived: sum of 2 quarters · filed 2023-11-09 | $1.78M 10-Q · filed 2023-11-09 | $1.80M 10-Q · filed 2022-11-08 | $2.56M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | $600.00K 10-Q · filed 2022-08-08 | $1.10M 10-Q · filed 2022-08-08 | $1.90M derived: sum of 3 quarters · filed 2024-02-27 | $2.60M derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2022-03-31 | $700.00K 10-Q · filed 2023-05-09 | $600.00K 10-Q · filed 2022-05-09 | $1.30M derived: sum of 2 quarters · filed 2024-02-27 | $2.00M derived: sum of 3 quarters · filed 2024-02-27 | $2.60M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2021-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.30M derived: sum of 2 quarters · filed 2024-02-27 | $1.90M derived: sum of 3 quarters · filed 2024-02-27 | $2.30M 10-K · filed 2024-02-27 | |||
| 2021-09-30 | $700.00K 10-Q · filed 2022-11-08 | $1.30M derived: sum of 2 quarters · filed 2022-11-08 | $1.70M 10-Q · filed 2022-11-08 | ||||
| 2021-06-30 | $600.00K 10-Q · filed 2022-08-08 | $1.20M 10-Q · filed 2022-08-08 | |||||
| 2021-03-31 | $600.00K 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |